We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Novel Risk Genes Identified for Bipolar Disorder

By LabMedica International staff writers
Posted on 10 Feb 2017
Bipolar disorder (BD) is a common psychiatric disorder characterized by mood swings between positive manic/hypomanic and negative/depressive states, with a lifetime prevalence of more than 1%.

Although epidemiological studies indicate that genetic components contribute to BD development, several genome-wide association studies (GWAS) identified limited number of susceptibility (risk) genes for BD, most of which are yet unidentified.

Image: The Infinium OmniExpress-24 Kit - This 24-sample BeadChip array offers exceptional throughput of thousands of samples per week, enabling powerful human genome-wide association studies (GWAS) (Photo courtesy of Illumina).
Image: The Infinium OmniExpress-24 Kit - This 24-sample BeadChip array offers exceptional throughput of thousands of samples per week, enabling powerful human genome-wide association studies (GWAS) (Photo courtesy of Illumina).

A collaboration of scientists under the auspices of those at Fujita Health University performed GWAS on 1,612 BD subjects, with 1,545 BD cases remaining after genotype quality control (QC) (Phase I); and the Phase II GWAS initially included 1,604 BD subjects, with 1,419 BD cases remaining after QC. For the Phase I study, the controls comprised 7,408 subjects who were genotyped in a previous GWAS as case subjects for five non-psychiatric disorders (cerebral aneurysm, esophageal cancer, endometrial cancer, chronic obstructive pulmonary disease and glaucoma) or as healthy volunteers. The controls for the Phase II study included 54,479 subjects who had also been genotyped as case subjects for 14 non-psychiatric disorders.

Genotyping was performed using the Illumina HumanOmniExpress v1 chip. The investigators identified a novel risk gene fatty acid desaturase genes (FADS1 and FADS2) for bipolar disorder via GWAS performed using samples collected in Japan of 2,964 cases and 61,887 comparison subjects. The function of this gene is well established: metabolism of lipids, including blood lipids (e.g., cholesterol and triglyceride) and omega3/6 polyunsaturated fatty acids (PUFA). The team then then conducted a meta-analysis between their samples and results from the publicly available BD GWAS database. They identified an additional novel gene for BD, nuclear family I/X (NFIX), and supported three previously implicated genes. The BD ‘risk’ effect is shared between Japanese and European populations. The study was published on January 24, 2017, in the journal Molecular Psychiatry.


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Latest Molecular Diagnostics News

First FDA-Approved Molecular Test to Screen Blood Donors for Malaria Could Improve Patient Safety

Fluid Biomarker Test Detects Neurodegenerative Diseases Before Symptoms Appear

New Genomic Method Helps Diagnose Patients with Unexplained Kidney Disease